BIOMARKER:

KMT2D mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

KMT2D mutation	Squamous Cell Carcinoma of Head and Neck	KMT2D mutation	Squamous Cell Carcinoma of Head and Neck	durvalumab + CP-675206 Sensitive: B - Late Trials durvalumab + CP-675206 Sensitive : B	durvalumab + CP-675206 Sensitive: B - Late Trials durvalumab + CP-675206 Sensitive : B
KMT2D mutation	Follicular Lymphoma	KMT2D mutation	Follicular Lymphoma	R-CHOP Resistant: C3 – Early Trials R-CHOP Resistant : C3	R-CHOP Resistant: C3 – Early Trials R-CHOP Resistant : C3
KMT2D mutation	Diffuse Large B Cell Lymphoma	KMT2D mutation	Diffuse Large B Cell Lymphoma	chidamide Resistant: C3 – Early Trials chidamide Resistant : C3	chidamide Resistant: C3 – Early Trials chidamide Resistant : C3
KMT2D mutation	Diffuse Large B Cell Lymphoma	KMT2D mutation	Diffuse Large B Cell Lymphoma	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3
KMT2D mutation	Marginal Zone Lymphoma	KMT2D mutation	Marginal Zone Lymphoma	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3
KMT2D mutation	Colorectal Cancer	KMT2D mutation	Colorectal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KMT2D mutation	Non Small Cell Lung Cancer	KMT2D mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KMT2D mutation	Colorectal Cancer	KMT2D mutation	Colorectal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KMT2D mutation	Cervical Cancer	KMT2D mutation	Cervical Cancer	anlotinib + sintilimab Sensitive: C3 – Early Trials anlotinib + sintilimab Sensitive : C3	anlotinib + sintilimab Sensitive: C3 – Early Trials anlotinib + sintilimab Sensitive : C3
KMT2D mutation	Triple Negative Breast Cancer	KMT2D mutation	Triple Negative Breast Cancer	cyclophosphamide + epirubicin Resistant: C3 – Early Trials cyclophosphamide + epirubicin Resistant : C3	cyclophosphamide + epirubicin Resistant: C3 – Early Trials cyclophosphamide + epirubicin Resistant : C3
KMT2D mutation	Chronic Lymphocytic Leukemia	KMT2D mutation	Chronic Lymphocytic Leukemia	decitabine Sensitive: D – Preclinical decitabine Sensitive : D	decitabine Sensitive: D – Preclinical decitabine Sensitive : D
KMT2D mutation	Chronic Lymphocytic Leukemia	KMT2D mutation	Chronic Lymphocytic Leukemia	chidamide Sensitive: D – Preclinical chidamide Sensitive : D	chidamide Sensitive: D – Preclinical chidamide Sensitive : D
KMT2D mutation	Chronic Lymphocytic Leukemia	KMT2D mutation	Chronic Lymphocytic Leukemia	ibrutinib + chidamide Sensitive: D – Preclinical ibrutinib + chidamide Sensitive : D	ibrutinib + chidamide Sensitive: D – Preclinical ibrutinib + chidamide Sensitive : D
KMT2D mutation	Chronic Lymphocytic Leukemia	KMT2D mutation	Chronic Lymphocytic Leukemia	ibrutinib + decitabine Sensitive: D – Preclinical ibrutinib + decitabine Sensitive : D	ibrutinib + decitabine Sensitive: D – Preclinical ibrutinib + decitabine Sensitive : D